X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs LUPIN LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA LUPIN LTD GSK PHARMA/
LUPIN LTD
 
P/E (TTM) x 66.4 28.3 234.9% View Chart
P/BV x 13.4 3.0 452.2% View Chart
Dividend Yield % 2.2 0.6 383.6%  

Financials

 GSK PHARMA   LUPIN LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
LUPIN LTD
Mar-18
GSK PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,7601,465 188.4%   
Low Rs2,040727 280.6%   
Sales per share (Unadj.) Rs339.0349.6 97.0%  
Earnings per share (Unadj.) Rs41.45.6 745.2%  
Cash flow per share (Unadj.) Rs45.929.6 155.2%  
Dividends per share (Unadj.) Rs35.005.00 700.0%  
Dividend yield (eoy) %1.50.5 319.7%  
Book value per share (Unadj.) Rs242.9300.3 80.9%  
Shares outstanding (eoy) m84.70452.08 18.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x7.13.1 225.8%   
Avg P/E ratio x57.9197.2 29.4%  
P/CF ratio (eoy) x52.337.1 141.1%  
Price / Book Value ratio x9.93.6 270.7%  
Dividend payout %84.590.0 93.9%   
Avg Mkt Cap Rs m203,280495,502 41.0%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m5,23428,647 18.3%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m28,715158,042 18.2%  
Other income Rs m5451,504 36.3%   
Total revenues Rs m29,260159,545 18.3%   
Gross profit Rs m5,05931,475 16.1%  
Depreciation Rs m38010,859 3.5%   
Interest Rs m22,044 0.1%   
Profit before tax Rs m5,22220,076 26.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m178-14,644 -1.2%   
Tax Rs m1,8922,885 65.6%   
Profit after tax Rs m3,5082,513 139.6%  
Gross profit margin %17.619.9 88.5%  
Effective tax rate %36.214.4 252.2%   
Net profit margin %12.21.6 768.4%  
BALANCE SHEET DATA
Current assets Rs m21,815122,095 17.9%   
Current liabilities Rs m15,99950,956 31.4%   
Net working cap to sales %20.345.0 45.0%  
Current ratio x1.42.4 56.9%  
Inventory Days Days6485 75.2%  
Debtors Days Days19120 15.6%  
Net fixed assets Rs m12,475129,876 9.6%   
Share capital Rs m847904 93.7%   
"Free" reserves Rs m19,726134,866 14.6%   
Net worth Rs m20,573135,771 15.2%   
Long term debt Rs m664,245 0.0%   
Total assets Rs m39,475263,054 15.0%  
Interest coverage x2,612.010.8 24,130.4%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.70.6 121.1%   
Return on assets %8.91.7 513.4%  
Return on equity %17.11.9 921.4%  
Return on capital %26.23.7 705.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56453,141 1.1%   
Fx outflow Rs m7,42919,335 38.4%   
Net fx Rs m-6,86533,807 -20.3%   
CASH FLOW
From Operations Rs m4,72817,512 27.0%  
From Investments Rs m-1,042-14,073 7.4%  
From Financial Activity Rs m-3,066-14,921 20.6%  
Net Cashflow Rs m620-11,482 -5.4%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 50.7 0.2 25,350.0%  
Indian inst/Mut Fund % 10.2 11.3 90.3%  
FIIs % 23.8 31.9 74.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.1 152.5%  
Shareholders   102,036 98,259 103.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS